These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10213347)

  • 1. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
    Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W
    Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon.
    Tomai F; Danesi A; Ghini AS; Crea F; Perino M; Gaspardone A; Ruggeri G; Chiariello L; Gioffrè PA
    Eur Heart J; 1999 Feb; 20(3):196-202. PubMed ID: 10082152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of myocardial protection in type 2 diabetic patients.
    Lee TM; Chou TF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.
    Tomai F; Crea F; Gaspardone A; Versaci F; De Paulis R; Penta de Peppo A; Chiariello L; Gioffrè PA
    Circulation; 1994 Aug; 90(2):700-5. PubMed ID: 8044938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
    Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
    Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sulphonylurea derivatives and the cardiovascular system].
    Filipiak KJ
    Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
    Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
    Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
    Holstein A; Plaschke A; Hammer C; Egberts EH
    Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris.
    Ovünç K
    Clin Cardiol; 2000 Jul; 23(7):535-9. PubMed ID: 10894443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty.
    Lee TM; Su SF; Chou TF; Lee YT; Tsai CH
    Circulation; 2002 Jan; 105(3):334-40. PubMed ID: 11804989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K; Végh A; Krause E; Papp JG
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
    González-Ortiz M; Martínez-Abundis E;
    Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance.
    Charpentier G; Fleury F; Dubroca I; Vaur L; Clerson P
    Diabetes Metab; 2005 Apr; 31(2):189-95. PubMed ID: 15959425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Massi-Benedetti M; Herz M; Pfeiffer C
    Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
    Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B.
    Schiekofer S; Rudofsky G; Andrassy M; Schneider J; Chen J; Isermann B; Kanitz M; Elsenhans S; Heinle H; Balletshofer B; Häring HU; Schleicher E; Nawroth PP; Bierhaus A
    Diabetes Obes Metab; 2003 Jul; 5(4):251-61. PubMed ID: 12795658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
    J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.